ArticleJournal of the Endocrine Society2021
Activation of Vasopressin System During COVID-19 is Associated With Adverse Clinical Outcomes: An Observational Study.
Article in Journal of the Endocrine Society, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 27 citations in OpenAlex.
- Reassessing the Role of Copeptin in Emergency Department Admissions for Hypotonic Hyponatremia.The Journal of clinical endocrinology and metabolism · 2025Article
- Vasopressin Contributes to Respiratory and Cardiovascular Regulation in Spontaneously Hypertensive and Normotensive Rats.Journal of clinical medicine · 2025Article
- A New Biomarker Copeptin in Determining Disease Severity in COVID-19.Infectious diseases & clinical microbiology · 2024Article
- Effectiveness of Copeptin, MR-proADM and MR-proANP in Predicting Adverse Outcomes, Alone and in Combination with Traditional Severity Scores, a Secondary Analysis in COVID-19 Patients Requiring Intensive Care Admission.Journal of clinical medicine · 2024Article
- Research progress of biomarkers in evaluating the severity and prognostic value of severe pneumonia in children.Frontiers in pediatrics · 2024Review
- Review novel insights into the diagnostic and prognostic function of copeptin in daily clinical practice.Molecular biology reports · 2023Review
- Blood urea nitrogen - independent marker of mortality in sepsis.Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia · 2023Article
- Association of vasopressors with mortality in critically ill patients with COVID-19: a systematic review and meta-analysis.Anesthesiology and perioperative science · 2023Review
- High level of psychological stress in COVID-19 recovered individuals: role of copeptin as a potential biomarker.Frontiers in psychology · 2023Article
- Sex-specific issues of central and peripheral arginine-vasopressin concentrations in neurocritical care patients.BMC neuroscience · 2022Article
- Endocannabinoid System in the Neuroendocrine Response to Lipopolysaccharide-induced Immune Challenge.Journal of the Endocrine Society · 2022Review
- Utility of cardiac bioenzymes in predicting cardiovascular outcomes in SARS-CoV-2.World journal of virology · 2022Article
- Copeptin: a neuroendocrine biomarker of COVID-19 severity.Biomarkers in medicine · 2022Article
- Prognostic value of copeptin and mid-regional proadrenomedullin in COVID-19-hospitalized patients.European journal of clinical investigation · 2022Article
- Review
- Disulfiram inhibits neutrophil extracellular trap formation and protects rodents from acute lung injury and SARS-CoV-2 infection.JCI insight · 2022Review
- Potential of Endogenous Oxytocin in Endocrine Treatment and Prevention of COVID-19.Frontiers in endocrinology · 2022Review
- Arginine vasopressin and pathophysiology of COVID-19: An innovative perspective.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021Review
- Vasopressin and Breathing: Review of Evidence for Respiratory Effects of the Antidiuretic Hormone.Frontiers in physiology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundActivation of the vasopressin system plays a key role for the maintenance of osmotic, cardiovascular, and stress hormone homeostasis during disease. We investigated levels of copeptin, the C-terminal segment of the vasopressin prohormone, that mirrors the production rate of vasopressin in patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
methodsWe measured levels of copeptin on admission and after days 3/4, 5/6, and 7/8 in 74 consecutive hospitalized adult COVID-19 patients and compared its prognostic accuracy to that of patients with community-acquired pneumonia (n = 876) and acute or chronic bronchitis (n = 371) from a previous study by means of logistic regression analysis. The primary endpoint was all-cause 30-day mortality.
resultsMedian admission copeptin levels in COVID-19 patients were almost 4-fold higher in nonsurvivors compared with survivors (49.4 pmol/L [iterquartile range (IQR) 24.9-68.9 pmol/L] vs 13.5 pmol/L [IQR 7.0-26.7 pmol/L]), resulting in an age- and gender-adjusted odds ratio of 7.0 (95% confidence interval [CI] 1.2-40.3),
conclusionsA pronounced activation of the vasopressin system in COVID-19 patients is associated with an adverse clinical course in COVID-19 patients. This finding, however, is not unique to COVID-19 but similar to other types of respiratory infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.